The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. - Wikidata - awgldk - TriplyDB

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.

http://www.wikidata.org/entity/Q40749802

about

Long-term drug treatment for obesity: a systematic and clinical review Long-term effects of weight-reducing drugs in people with hypertension Long-term effects of weight-reducing drugs in hypertensive patients Long-term effects of weight-reducing drugs in hypertensive patients Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus Long-term pharmacotherapy for obesity and overweight Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials Tackling obesity: new therapeutic agents for assisted weight loss.Extracts from "Clinical Evidence". Obesity.Current and investigational antiobesity agents and obesity therapeutic treatment targets.Dietary treatment and long-term weight loss and maintenance in type 2 diabetes.Impact of orlistat-induced weight loss on diastolic function and heart rate variability in severely obese subjects with diabetes.Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis.Orlistat use in type 2 diabetes.Obesity in the elderly--a future matter of concern?Anti-obesity drug development.Evaluation of efficacy and safety of orlistat in obese patients.Treatment of obesity: an update on anti-obesity medications.Pharmacotherapy for dyslipidaemia--current therapies and future agents.A systematic review of the clinical effectiveness of orlistat used for the management of obesity.What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions.Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions.Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors.Obesity management: update on orlistat.Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis.Industry funding and the reporting quality of large long-term weight loss trials.Current pharmacotherapeutic concepts for the treatment of obesity in adults.Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension.Meta- and cost-effectiveness analysis of commercial weight loss strategies.Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels.Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions.The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors.Effects of orlistat on obesity-related diseases - a six-month randomized trial.Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change.A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.Effects of Weight Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-Analysis.The effect of orlistat on weight reduction in obese and overweight Korean patients.

P2860

Q22253010-42BAA4E7-6283-40BA-AD76-1D1A9982A3B2 Q24186054-48F97503-A991-49AA-A9F1-C7FC9411E6D9 Q24200212-4F5F1DD9-652F-4BDC-97AE-1BF8D97BFDC4 Q24239850-283A830F-E85E-4AB4-AB5C-697254BD9DC7 Q24245173-8C074DFA-5638-4064-9D1B-7B237C04084C Q24247723-DB4EA25F-848D-4D75-9F5C-7CF93CF11097 Q28480564-6E5B1793-C447-4C34-8F26-EEF84DC9810D Q30401145-3DF3A677-7A59-46EC-8AD0-E44FE7AD9C07 Q33805817-0D1A6814-13B5-464A-8A63-FF13C759F9D4 Q34344786-E4D066ED-9A68-48F0-8DC2-974486D97730 Q34438263-A5F127E1-9361-474A-9B6F-64A4BA24833C Q34495544-07C646E1-B64B-421C-AD00-8B4443290AE2 Q34609349-85F6710C-D3F3-4236-AF57-1A0D4BB84B04 Q34709845-BD302C29-18BF-4DD9-A4F6-4887275E49DE Q34742857-18969AA5-3C64-4689-9CDF-DE89C721635D Q34841680-F92F0681-8474-4402-8E74-1066A7A688E4 Q35073399-706B0F5D-FAB8-4E94-B75D-3B529FB1909D Q35074214-03AEDCB1-097B-46FE-A07A-24D41E11CBCF Q35574960-67DEF102-7486-4024-A6FA-EA9ADC743310 Q35669802-4073642D-AC19-4A3B-B5A5-2CC27A555ED1 Q35834676-8B5E3518-B5A5-4B10-BB8B-E9D45C231F8D Q35926351-FA82D8D3-710D-431D-8C61-AAC83C22A527 Q36051581-50FD3279-701B-43F0-9899-2F4E2F7CA875 Q36551394-F74A19FC-D9CD-4287-90BD-49F0CB5C467D Q36596807-7EF79A60-8FEF-4C01-AAA3-20432EE396E3 Q37193596-BC254F32-029C-4DF4-9E28-06B95918D199 Q37246642-994D75FA-4B57-4F74-9922-85EBEA86300C Q37368688-69029959-614F-4E2C-9832-161BA405BCA3 Q38092017-47D20360-B65C-4A47-AFCF-FA9FC3A0C6B5 Q38222981-E0DCE916-E294-48F9-A8D8-D73BDE0DC632 Q39699152-09077BE7-4C25-4731-9384-DF131F9D5642 Q42637589-5C147325-90D2-4654-9A7B-859B3D7C0734 Q44053877-94D450AF-613B-4E75-840A-3283CBF16B6A Q44198041-617E11FF-EE3F-4CC3-ADB9-2B29FBDB2111 Q44393974-9FDAD679-132B-4664-A9A2-001686D3EB6E Q45002826-E4A86EB8-2154-40A0-AA78-9F2EB1101ADD Q45271304-329DADBB-C650-4202-9211-E56B6F4D69B6 Q46447210-87463D8E-C173-4BA4-9B9E-5442D378E266 Q47172247-AAA97BAA-2C2C-4F7A-A716-EB5747F38C42 Q47224342-CCA3F4C8-4020-497E-87C3-49C78413D8E7

P2860

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.

http://www.wikidata.org/entity/Q40749802

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

The effect of orlistat on body ...... Swedish Multimorbidity Study.

@en

type

label

The effect of orlistat on body ...... Swedish Multimorbidity Study.

@en

prefLabel

The effect of orlistat on body ...... Swedish Multimorbidity Study.

@en

P1433

Q40749802-714649C9-E533-4002-9785-D5D793683248

P1476

Q40749802-BD41D1A8-532E-4E36-80BF-6B8A123D10BF

P2093

Q40749802-35964425-45F5-4E2F-828A-CDA9128DDA33

P2860

Q40749802-10545116-1E0D-4AB3-A797-053E6DD231F2

Q40749802-10CF5ACC-C0F5-4514-B1EB-4A4219D043F5

Q40749802-3527E9AF-0C35-4214-B796-4DAA70D54590

Q40749802-395CBB81-ECC4-41BC-852E-76CB36AC5CFB

Q40749802-3DF5CACE-A6E2-40C4-9FA1-849C2A6A6D91

Q40749802-486BEDEE-1A75-4E86-8714-337A2357C31E

Q40749802-5007288A-7FA5-4DA5-BFA3-71AD0EF09DCA

Q40749802-54247E8E-3CFB-4A1F-87AD-C99CA0E8E273

Q40749802-63DECCFC-8E06-4AB4-BAEA-0B2DD0A3DD60

Q40749802-78D0C4F0-BA1A-4372-8F4C-C2ADA6E3479A

P304

Q40749802-0B58E166-55BD-44DC-A344-7A09219D31EB

P31

Q40749802-AAEDAC89-19D7-474A-8F43-4736765C3017

P356

Q40749802-A69A322D-1467-4841-84C2-F71C529DF4DC

P407

Q40749802-9B10B6FF-DB6B-44FF-A0E4-43BD23C60E8C

P433

Q40749802-0E1DF1EA-A3B1-49E9-B8DF-009BF247AE5F

P478

Q40749802-88B71057-7671-4EB5-BE4E-4CF2525B1318

P577

Q40749802-9A35267A-8E3A-46A5-B9AB-84F4B349FBD9

P5875

Q40749802-08D21E82-DAA6-4BE7-8251-A66E7D05C505

P698

Q40749802-E599BDE5-8037-4B5A-9AF6-69CA11E73A64

P921

Q40749802-1E81194F-A063-4F0B-A8C1-4AD6BF06C993

Q40749802-89225745-F2E1-4E70-B420-CADF28BCE6E0

P356

J.1365-2796.2000.00720.X

P1433

Journal of Internal Medicine

P1476

The effect of orlistat on body ...... Swedish Multimorbidity Study.

@en

P2093

Lindgärde F

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group.

Short-term medical benefits and adverse effects of weight loss.

A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity.

Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital.

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

P304

245-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2796.2000.00720.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

248

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12349903

http://www.w3.org/2001/XMLSchema#string

P698

10971792

http://www.w3.org/2001/XMLSchema#string

P921